Metaclipse Therapeutics Corporation Email Format

Biotechnology ResearchTexas, United States11-50 Employees

Metaclipse Therapeutics Corporation is a clinical-stage biotechnology company focused on immune-based therapies for cancer and vaccines to prevent infectious diseases, leveraging proprietary biological adjuvants. Its personalized immunotherapy platform, Membrex, has produced encouraging preclinical results across several solid tumors, with Phase 1 trials underway for triple-negative breast cancer and head and neck cancer (HNSCC). The work seeks to address unmet needs in oncology and vaccinology through innovative use of adjuvants in both therapeutic and preventive vaccines.

Based in Houston, Texas, the firm operates with a small team within the biotechnology research sector. Its programs target cancer patients and infectious disease prevention, aiming to offer new immunotherapy options and vaccines for broader clinical use. Public notices from 2020 indicate activity in developing a COVID-19 vaccine and an influenza vaccine using a virus-like particle approach, reflecting ongoing exploratory work in its infectious disease portfolio.

Get verified Metaclipse Therapeutics Corporation emails free

Company overview Employee directory